Scientists headed by a team at the University of British Columbia (UBC) have developed a new approach to drug design that can deliver therapeutics directly to a specific part of the gastrointestinal ...
The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...
As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...
Transcription Factors (TFs) are pivotal regulators of gene expression and have been implicated in a variety of diseases, including cancer, neurological disorders, autoimmune conditions, and metabolic ...
Zenas BioPharma, Inc. (ZBIO) is gearing up to report data from several of its ongoing studies using its differentiated B-Cell targeting drug obexelimab for autoimmune disorders. In particular, the ...
Sutter Hill Ventures-led round will accelerate drug pipeline development and advance commercialization efforts, bringing science a step closer to targeting aging REDWOOD CITY, Calif.--(BUSINESS WIRE)- ...
Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression on the surface of cells in gastrointestinal cancers makes it an attractive ...
Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of ...
In a preclinical study, two drugs targeting 'zombie cells' have been shown to treat the underlying cause of chronic low back pain. The condition affects millions of people worldwide. Current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback